Skip to content
Home/Companies/Biotech/Souffle Therapeutics

Souffle Therapeutics

Biotech·United States·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Souffle Therapeutics?

Souffle Therapeutics is an American Biotech company, currently owned by Leaps by Bayer since 2025.

Hand-verified · updated 2026-07-07

Open JSON · CC-BY
Leaps by Bayer
Investor
Leaps by Bayer
Leaps by Bayer · 2015 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Leaps by Bayer

Other portfolio companies in the same fund.

Celea Therapeutics
Celea Therapeutics
Active
BiotechUS· 2026
Leaf Agriculture
Active
ClimateTechUS· 2026
Sabanto
Active
AgTechUS· 2026
SonoThera
SonoThera
Active
BiotechUS· 2026
WellTheory
WellTheory
Active
HealthTechUS· 2025
CORXEL
Corxel
Active
PharmaChina· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Souffle Therapeutics?

Souffle Therapeutics is currently owned by Leaps by Bayer, through Leaps by Bayer, since 2025.

When did Leaps by Bayer acquire Souffle Therapeutics?

Leaps by Bayer acquired Souffle Therapeutics in 2025.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue